Cannabinoid oil cost-effective choice for Dravet syndrome in Canada

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      containing a 20:1 ratio of cannabidiol to delta-9-tretrahydrocanabidiol, with an estimated concentration of 16.0−24.0 mg/mL

    Reference

    1. Elliott J, et al. Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. PharmacoEconomics : 14 May 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00923-5

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Cannabinoid oil cost-effective choice for Dravet syndrome in Canada. PharmacoEcon Outcomes News 854, 9 (2020). https://doi.org/10.1007/s40274-020-6839-9

    Download citation